Cargando…
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer
Breast cancer is a heterogeneous disease with distinct clinical and molecular characteristics. Scientific advances in molecular subtype differentiation support the understanding of cellular signaling, crosstalk, proliferation, survival, migration, and invasion mechanisms, allowing the development of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779412/ https://www.ncbi.nlm.nih.gov/pubmed/36555156 http://dx.doi.org/10.3390/ijms232415515 |
_version_ | 1784856603345813504 |
---|---|
author | Crocamo, Susanne Binato, Renata dos Santos, Everton Cruz de Paula, Bruno Abdelhay, Eliana |
author_facet | Crocamo, Susanne Binato, Renata dos Santos, Everton Cruz de Paula, Bruno Abdelhay, Eliana |
author_sort | Crocamo, Susanne |
collection | PubMed |
description | Breast cancer is a heterogeneous disease with distinct clinical and molecular characteristics. Scientific advances in molecular subtype differentiation support the understanding of cellular signaling, crosstalk, proliferation, survival, migration, and invasion mechanisms, allowing the development of new molecular drug targets. The breast cancer subtype with super expression and/or amplification of human growth factor receptor 2 (HER2) is clinically aggressive, but prognosis significantly shifted with the advent of anti-HER2 targeted therapy. Zoledronic-acid (ZOL) combined with a neoadjuvant Trastuzumab-containing chemotherapy regimen (Doxorubicin, Cyclophosphamide followed by Docetaxel, Trastuzumab) increased the pCR rate in a RH-positive/ HER2-positive subgroup, according to the phase II Zo-NAnTax trial. To verify genes that could be related to this response, a microarray assay was performed finding 164 differentially expressed genes. Silico analysis of these genes showed signaling pathways related to growth factors, apoptosis, invasion, and metabolism, as well as differentially expressed genes related to estrogen response. In addition, the RAC3 gene was found to interact with the MVD gene, a member of the mevalonate pathway. Taken together, these results indicate that RH-positive/ HER2-positive patients present gene alterations before treatment, and these could be related to the improvement of pCR. |
format | Online Article Text |
id | pubmed-9779412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97794122022-12-23 Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer Crocamo, Susanne Binato, Renata dos Santos, Everton Cruz de Paula, Bruno Abdelhay, Eliana Int J Mol Sci Article Breast cancer is a heterogeneous disease with distinct clinical and molecular characteristics. Scientific advances in molecular subtype differentiation support the understanding of cellular signaling, crosstalk, proliferation, survival, migration, and invasion mechanisms, allowing the development of new molecular drug targets. The breast cancer subtype with super expression and/or amplification of human growth factor receptor 2 (HER2) is clinically aggressive, but prognosis significantly shifted with the advent of anti-HER2 targeted therapy. Zoledronic-acid (ZOL) combined with a neoadjuvant Trastuzumab-containing chemotherapy regimen (Doxorubicin, Cyclophosphamide followed by Docetaxel, Trastuzumab) increased the pCR rate in a RH-positive/ HER2-positive subgroup, according to the phase II Zo-NAnTax trial. To verify genes that could be related to this response, a microarray assay was performed finding 164 differentially expressed genes. Silico analysis of these genes showed signaling pathways related to growth factors, apoptosis, invasion, and metabolism, as well as differentially expressed genes related to estrogen response. In addition, the RAC3 gene was found to interact with the MVD gene, a member of the mevalonate pathway. Taken together, these results indicate that RH-positive/ HER2-positive patients present gene alterations before treatment, and these could be related to the improvement of pCR. MDPI 2022-12-08 /pmc/articles/PMC9779412/ /pubmed/36555156 http://dx.doi.org/10.3390/ijms232415515 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Crocamo, Susanne Binato, Renata dos Santos, Everton Cruz de Paula, Bruno Abdelhay, Eliana Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer |
title | Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer |
title_full | Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer |
title_fullStr | Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer |
title_full_unstemmed | Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer |
title_short | Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer |
title_sort | translational results of zo-nantax: a phase ii trial of neoadjuvant zoledronic acid in her2-positive breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779412/ https://www.ncbi.nlm.nih.gov/pubmed/36555156 http://dx.doi.org/10.3390/ijms232415515 |
work_keys_str_mv | AT crocamosusanne translationalresultsofzonantaxaphaseiitrialofneoadjuvantzoledronicacidinher2positivebreastcancer AT binatorenata translationalresultsofzonantaxaphaseiitrialofneoadjuvantzoledronicacidinher2positivebreastcancer AT dossantosevertoncruz translationalresultsofzonantaxaphaseiitrialofneoadjuvantzoledronicacidinher2positivebreastcancer AT depaulabruno translationalresultsofzonantaxaphaseiitrialofneoadjuvantzoledronicacidinher2positivebreastcancer AT abdelhayeliana translationalresultsofzonantaxaphaseiitrialofneoadjuvantzoledronicacidinher2positivebreastcancer |